Last reviewed · How we verify

Continuous remifentanil Infusion

Kaohsiung Veterans General Hospital. · FDA-approved active Small molecule

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intraoperative analgesia during general anesthesia, Sedation and analgesia in mechanically ventilated patients in intensive care settings.

At a glance

Generic nameContinuous remifentanil Infusion
SponsorKaohsiung Veterans General Hospital.
Drug classOpioid agonist
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Analgesia
PhaseFDA-approved

Mechanism of action

Remifentanil activates mu opioid receptors, which inhibit pain signal transmission and modulate consciousness. It is a rapid-onset, short-acting opioid metabolized by non-specific plasma and tissue esterases, allowing for quick offset even with continuous infusion. This pharmacokinetic profile makes it particularly suitable for intraoperative and critical care analgesia where rapid titration is needed.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: